Stryker to invest $400m in CMR Surgical with option to buy UK robot surgery firm
US-listed medtech Stryker is set to invest around $400m in UK robotic surgery company CMR Surgical, with an option to acquire it outright and exclusive US sales rights for its robot-assisted surgery system.
The arrangement would give Stryker a commercial role in the United States for CMR's robot-assisted surgery system while also creating a route to full ownership of the UK company. The investment is described as approximately $400 million. Sifted did not say when the investment would be completed or what conditions would apply to the acquisition option.
CMR Surgical is identified in the report as a UK robotic surgery company, and Stryker is described as a US-listed medtech. The report did not provide a precise valuation for CMR Surgical, nor did it state whether the $400 million would be paid in a single tranche or in stages. It also did not say whether the option to acquire CMR outright has a deadline or whether it is subject to regulatory approval.
The Sifted report was published under the headline "Stryker to invest $400m in CMR Surgical, with option to buy it outright." Its subheading said the listed medtech will act as exclusive US sales agent for CMR's robot-assisted surgery system. The report did not include the total valuation of CMR Surgical or the size of the stake Stryker would receive for the investment. It also did not identify any other investors or say whether existing shareholders would be affected.
Neither company was quoted in the report. The reported deal would combine a financial investment with an exclusive US sales mandate, giving Stryker a direct channel for CMR's robot-assisted surgery system in the US market and a potential path to buy the company. The terms beyond the approximate investment figure and the sales agency role were not disclosed in the Sifted report.